| 000 | 01874nam a2200145Ia 4500 | ||
|---|---|---|---|
| 005 | 20260209120130.0 | ||
| 008 | 260209s9999||||xx |||||||||||||| ||und|| | ||
| 100 | _aPriya Vijay | ||
| 245 | 0 | _aCompetition issues in the pharmaceutical sector and right to access to medicine | |
| 260 |
_aBangaloreBangalore _bNLSIU _c2012 |
||
| 300 | _a114 p. ; 25 cm. | ||
| 505 | _aTable of Contents Backdrop of the study; Chapter One ; Pharmaceutical sector and Competition: different aspects ; History of pharmaceutical sector in India; II) Why to be regulated; II. Competition in Pharma sector and poverty and role of government; Advantages of Competition regime; Object of regulatory Control; Drug pricing & Competition; Chapter Two ; Regulatory Framework of the Pharmaceutical Sector ; Relevant legislations Rules ; Some Relevant policies ; Regulatory agencies ; Chapter Three ; Competition Issues in Pharmaceutical sector ; STATUTORY PROVISIONS: Anti-competitive agreements and collusive practices ; Cartel- ; Abuse of dominance ; Regulation of Combination; Chapter Four ; Merger & Acquisitions of Pharm a Companies ; Incentives for Mergers and Acquisitions by Indian companies ; Sun Pharmaceuticals Industries/Taro Pharmaceutical Industries ; Mylan Laboratories/E. Merck OHG ; Case 2- Daiichi-Ranbaxy Acquisition Deal; Piramal Bought by Abbot Laboratories; Acquisition of Dabur Pharma Fresenus Kabi ; Shantha Biotech acquired; Chapter Five ; ..,/issues relating to patenting and compulsory licencing; Chapter Six; Right to access to medicine and pricing issues of Drug; Suggestions that can help to have better access to medicine; Price regulation of Drugs; The genericmedicine pricing & Competition ; Pricing of Vaccines ; Conclusion; Bibliography. | ||
| 700 | _aDr. Sairam Bhat - GuideDr. Sairam Bhat - Guide | ||
| 856 | _uhttps://dans.nls.ac.in/handle/123456789/1951 | ||
| 999 |
_c217036 _d217036 |
||